| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA, Viral | 28 | 2016 | 311 | 3.070 |
Why?
|
| AIDS Dementia Complex | 23 | 2017 | 116 | 2.780 |
Why?
|
| HIV-1 | 30 | 2019 | 755 | 2.250 |
Why?
|
| HIV Infections | 45 | 2023 | 2586 | 1.980 |
Why?
|
| Lymphoma, Non-Hodgkin | 8 | 2016 | 40 | 1.340 |
Why?
|
| Monocytes | 16 | 2019 | 277 | 1.320 |
Why?
|
| Anal Canal | 4 | 2019 | 32 | 1.320 |
Why?
|
| Anus Neoplasms | 4 | 2019 | 44 | 1.160 |
Why?
|
| Burkitt Lymphoma | 10 | 2018 | 25 | 1.110 |
Why?
|
| Lymphoma, B-Cell | 9 | 2021 | 28 | 1.080 |
Why?
|
| Anti-HIV Agents | 11 | 2019 | 486 | 1.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2021 | 220 | 1.040 |
Why?
|
| Leukocytes, Mononuclear | 9 | 2019 | 247 | 1.020 |
Why?
|
| Cognition Disorders | 11 | 2015 | 243 | 0.960 |
Why?
|
| Antiretroviral Therapy, Highly Active | 14 | 2023 | 229 | 0.960 |
Why?
|
| Pediatrics | 3 | 2020 | 70 | 0.940 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 83 | 0.910 |
Why?
|
| Humans | 106 | 2023 | 43102 | 0.780 |
Why?
|
| Papillomavirus Infections | 4 | 2018 | 376 | 0.770 |
Why?
|
| Awards and Prizes | 2 | 2020 | 28 | 0.720 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2018 | 11 | 0.710 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 259 | 0.700 |
Why?
|
| HIV Seropositivity | 5 | 2019 | 196 | 0.670 |
Why?
|
| Blood-Brain Barrier | 2 | 2019 | 173 | 0.670 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 15 | 0.670 |
Why?
|
| DNA, Neoplasm | 10 | 2004 | 92 | 0.650 |
Why?
|
| Polymerase Chain Reaction | 10 | 2007 | 455 | 0.640 |
Why?
|
| Adult | 45 | 2021 | 13872 | 0.630 |
Why?
|
| Male | 57 | 2021 | 23409 | 0.610 |
Why?
|
| Program Development | 1 | 2020 | 240 | 0.590 |
Why?
|
| Internship and Residency | 1 | 2020 | 146 | 0.580 |
Why?
|
| Human papillomavirus 16 | 1 | 2018 | 37 | 0.570 |
Why?
|
| Viral Load | 11 | 2018 | 348 | 0.560 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2019 | 95 | 0.560 |
Why?
|
| Proviruses | 4 | 2007 | 35 | 0.550 |
Why?
|
| Family Characteristics | 1 | 2019 | 126 | 0.550 |
Why?
|
| Female | 53 | 2021 | 24698 | 0.550 |
Why?
|
| Mass Screening | 3 | 2019 | 541 | 0.550 |
Why?
|
| Early Detection of Cancer | 3 | 2019 | 449 | 0.540 |
Why?
|
| Lymphoma | 3 | 2007 | 41 | 0.530 |
Why?
|
| Child | 19 | 2021 | 3443 | 0.530 |
Why?
|
| Macrophages | 7 | 2014 | 529 | 0.520 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 269 | 0.500 |
Why?
|
| Sex Factors | 1 | 2020 | 1028 | 0.500 |
Why?
|
| Mitochondria | 3 | 2008 | 523 | 0.500 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2016 | 3 | 0.490 |
Why?
|
| Neurofibromatosis 1 | 1 | 2016 | 5 | 0.480 |
Why?
|
| Lymphoma, AIDS-Related | 7 | 2004 | 13 | 0.460 |
Why?
|
| Middle Aged | 36 | 2019 | 12222 | 0.460 |
Why?
|
| Schools, Medical | 3 | 2020 | 208 | 0.460 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 81 | 0.460 |
Why?
|
| DNA, Mitochondrial | 4 | 2008 | 191 | 0.450 |
Why?
|
| Virus Integration | 6 | 2004 | 65 | 0.450 |
Why?
|
| Herpesvirus 4, Human | 11 | 2004 | 36 | 0.440 |
Why?
|
| B-Lymphocytes | 2 | 2007 | 189 | 0.440 |
Why?
|
| Adolescent | 15 | 2021 | 6081 | 0.400 |
Why?
|
| Hodgkin Disease | 2 | 2004 | 13 | 0.400 |
Why?
|
| Hawaii | 14 | 2020 | 2011 | 0.390 |
Why?
|
| Acquired Immunodeficiency Syndrome | 9 | 2014 | 226 | 0.390 |
Why?
|
| Papillomaviridae | 2 | 2012 | 142 | 0.360 |
Why?
|
| Neuropsychological Tests | 11 | 2018 | 284 | 0.360 |
Why?
|
| Insulin Resistance | 4 | 2020 | 201 | 0.360 |
Why?
|
| Cytosol | 1 | 2011 | 97 | 0.350 |
Why?
|
| Brain | 5 | 2014 | 1472 | 0.340 |
Why?
|
| Neoplasm, Residual | 4 | 2015 | 17 | 0.320 |
Why?
|
| RNA, Viral | 5 | 2018 | 321 | 0.320 |
Why?
|
| Child, Preschool | 8 | 2021 | 1546 | 0.310 |
Why?
|
| Base Sequence | 12 | 2007 | 983 | 0.310 |
Why?
|
| Adipose Tissue | 3 | 2014 | 182 | 0.300 |
Why?
|
| CD4 Lymphocyte Count | 10 | 2012 | 201 | 0.290 |
Why?
|
| Hospitals, Teaching | 1 | 2008 | 33 | 0.290 |
Why?
|
| Antigens, CD | 4 | 2018 | 127 | 0.270 |
Why?
|
| Cognition | 8 | 2018 | 473 | 0.270 |
Why?
|
| Sarcoma | 1 | 2007 | 11 | 0.260 |
Why?
|
| Tumor Virus Infections | 1 | 2007 | 22 | 0.260 |
Why?
|
| JC Virus | 1 | 2007 | 23 | 0.260 |
Why?
|
| Polyomavirus Infections | 1 | 2007 | 18 | 0.260 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2009 | 41 | 0.260 |
Why?
|
| HIV | 5 | 2020 | 100 | 0.260 |
Why?
|
| Cohort Studies | 14 | 2013 | 1759 | 0.260 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 2004 | 11 | 0.250 |
Why?
|
| Capsid Proteins | 1 | 2007 | 76 | 0.250 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 269 | 0.240 |
Why?
|
| DNA Primers | 6 | 2007 | 294 | 0.240 |
Why?
|
| Torque teno virus | 2 | 2002 | 9 | 0.240 |
Why?
|
| Cell Transformation, Viral | 2 | 2004 | 24 | 0.240 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2003 | 57 | 0.240 |
Why?
|
| DNA Virus Infections | 2 | 2002 | 16 | 0.240 |
Why?
|
| Chemokine CCL2 | 1 | 2006 | 95 | 0.230 |
Why?
|
| Hepatitis C | 2 | 2005 | 139 | 0.230 |
Why?
|
| HIV Wasting Syndrome | 1 | 2005 | 8 | 0.230 |
Why?
|
| Antigens, CD20 | 1 | 2004 | 3 | 0.220 |
Why?
|
| Virus Diseases | 1 | 2005 | 27 | 0.220 |
Why?
|
| Genes, myc | 6 | 2014 | 31 | 0.220 |
Why?
|
| Prognosis | 5 | 2021 | 861 | 0.220 |
Why?
|
| Chemokines | 1 | 2005 | 96 | 0.220 |
Why?
|
| Cross-Sectional Studies | 13 | 2019 | 3156 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2013 | 1019 | 0.210 |
Why?
|
| Biopsy | 3 | 2019 | 177 | 0.210 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2003 | 41 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 16 | 0.200 |
Why?
|
| CpG Islands | 1 | 2003 | 109 | 0.200 |
Why?
|
| Granulocytes | 1 | 2023 | 26 | 0.200 |
Why?
|
| Zidovudine | 1 | 2003 | 32 | 0.200 |
Why?
|
| Aging | 7 | 2023 | 783 | 0.200 |
Why?
|
| Neoplasms | 2 | 2005 | 1377 | 0.200 |
Why?
|
| Research Support as Topic | 2 | 2020 | 89 | 0.200 |
Why?
|
| Fetal Blood | 1 | 2003 | 48 | 0.190 |
Why?
|
| Proto-Oncogenes | 3 | 1994 | 19 | 0.190 |
Why?
|
| Case-Control Studies | 5 | 2018 | 1285 | 0.190 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2003 | 74 | 0.190 |
Why?
|
| Incidence | 4 | 2019 | 1078 | 0.190 |
Why?
|
| Blotting, Southern | 8 | 2007 | 68 | 0.180 |
Why?
|
| Placenta | 1 | 2003 | 117 | 0.180 |
Why?
|
| Lipodystrophy | 1 | 2001 | 7 | 0.180 |
Why?
|
| Herpesvirus 6, Human | 1 | 2001 | 5 | 0.180 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2003 | 117 | 0.180 |
Why?
|
| Neoplasm Staging | 4 | 2013 | 374 | 0.170 |
Why?
|
| Cerebral Cortex | 2 | 2013 | 306 | 0.170 |
Why?
|
| Longitudinal Studies | 7 | 2017 | 1063 | 0.170 |
Why?
|
| Anti-Retroviral Agents | 3 | 2018 | 160 | 0.170 |
Why?
|
| Young Adult | 7 | 2021 | 5080 | 0.170 |
Why?
|
| Professional Practice Location | 1 | 2020 | 17 | 0.170 |
Why?
|
| Bone Diseases | 1 | 2020 | 18 | 0.160 |
Why?
|
| Immunotherapy | 3 | 2018 | 144 | 0.160 |
Why?
|
| Aged | 11 | 2015 | 8214 | 0.160 |
Why?
|
| Cyclohexanes | 2 | 2023 | 30 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2003 | 403 | 0.160 |
Why?
|
| Liver | 1 | 2003 | 511 | 0.160 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 2 | 2014 | 31 | 0.160 |
Why?
|
| Infant | 4 | 2016 | 1175 | 0.160 |
Why?
|
| Models, Biological | 2 | 2018 | 712 | 0.160 |
Why?
|
| Translocation, Genetic | 3 | 1990 | 40 | 0.160 |
Why?
|
| Molecular Sequence Data | 9 | 2007 | 1542 | 0.150 |
Why?
|
| Carotid Arteries | 1 | 2019 | 36 | 0.150 |
Why?
|
| Medically Underserved Area | 1 | 2020 | 120 | 0.150 |
Why?
|
| Triazoles | 2 | 2023 | 102 | 0.150 |
Why?
|
| Receptors, IgG | 3 | 2014 | 53 | 0.150 |
Why?
|
| Pilot Projects | 4 | 2015 | 760 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2014 | 1600 | 0.150 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 14 | 0.150 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 22 | 0.150 |
Why?
|
| Risk Factors | 7 | 2020 | 3994 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2020 | 587 | 0.140 |
Why?
|
| Behavioral Research | 1 | 2019 | 41 | 0.140 |
Why?
|
| Viremia | 1 | 2018 | 44 | 0.140 |
Why?
|
| Galectins | 1 | 2018 | 30 | 0.140 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 440 | 0.140 |
Why?
|
| Salvage Therapy | 2 | 2016 | 10 | 0.140 |
Why?
|
| Minority Health | 1 | 2019 | 95 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 146 | 0.140 |
Why?
|
| Physicians | 1 | 2020 | 188 | 0.140 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 386 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2018 | 126 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2018 | 152 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2019 | 169 | 0.130 |
Why?
|
| Atrophy | 2 | 2014 | 51 | 0.130 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 23 | 0.130 |
Why?
|
| Rural Population | 1 | 2020 | 373 | 0.130 |
Why?
|
| Cell Movement | 2 | 2018 | 655 | 0.130 |
Why?
|
| Autopsy | 1 | 2016 | 48 | 0.130 |
Why?
|
| Biomedical Research | 2 | 2019 | 502 | 0.120 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 749 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 27 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 1991 | 31 | 0.120 |
Why?
|
| Minority Groups | 2 | 2019 | 690 | 0.110 |
Why?
|
| Algorithms | 1 | 2018 | 509 | 0.110 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 59 | 0.110 |
Why?
|
| Genes, Immunoglobulin | 3 | 1995 | 37 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 539 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 1994 | 6 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 1991 | 7 | 0.100 |
Why?
|
| Ferrosoferric Oxide | 1 | 2013 | 13 | 0.100 |
Why?
|
| HIV Seronegativity | 2 | 2005 | 41 | 0.100 |
Why?
|
| Exosomes | 1 | 2015 | 126 | 0.100 |
Why?
|
| Recurrence | 2 | 2011 | 152 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2015 | 307 | 0.100 |
Why?
|
| Inflammation | 1 | 2018 | 758 | 0.100 |
Why?
|
| Cerebellum | 1 | 2013 | 79 | 0.100 |
Why?
|
| Genotype | 2 | 2012 | 800 | 0.100 |
Why?
|
| Homosexuality, Male | 1 | 2018 | 486 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 1067 | 0.090 |
Why?
|
| Thailand | 4 | 2015 | 51 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 1994 | 140 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2011 | 60 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1271 | 0.090 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2011 | 6 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 14 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 234 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 56 | 0.090 |
Why?
|
| Anus Diseases | 1 | 2011 | 17 | 0.080 |
Why?
|
| Sarcoma, Kaposi | 2 | 2005 | 23 | 0.080 |
Why?
|
| Vincristine | 4 | 2014 | 14 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 497 | 0.080 |
Why?
|
| Prednisone | 4 | 2014 | 31 | 0.080 |
Why?
|
| Methotrexate | 4 | 2014 | 22 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 1991 | 61 | 0.080 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 14 | 0.080 |
Why?
|
| Apolipoprotein E4 | 2 | 2008 | 67 | 0.080 |
Why?
|
| Cyclophosphamide | 4 | 2014 | 59 | 0.080 |
Why?
|
| Gene Expression | 2 | 2014 | 701 | 0.080 |
Why?
|
| Niacin | 1 | 2010 | 23 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2010 | 21 | 0.080 |
Why?
|
| Bacteriocins | 1 | 2009 | 7 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2018 | 1621 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 61 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 99 | 0.080 |
Why?
|
| Vasodilation | 1 | 2010 | 64 | 0.080 |
Why?
|
| Doxorubicin | 4 | 2014 | 97 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2011 | 2544 | 0.080 |
Why?
|
| Complement System Proteins | 1 | 2009 | 25 | 0.080 |
Why?
|
| Education, Distance | 1 | 2010 | 46 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2007 | 719 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 3 | 2007 | 515 | 0.080 |
Why?
|
| Canarypox virus | 1 | 2009 | 4 | 0.080 |
Why?
|
| Leukemia, B-Cell | 1 | 2009 | 2 | 0.070 |
Why?
|
| Vaccinia virus | 1 | 2009 | 13 | 0.070 |
Why?
|
| Age Factors | 4 | 2018 | 1154 | 0.070 |
Why?
|
| Probability | 1 | 2009 | 82 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 2 | 2003 | 29 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2008 | 75 | 0.070 |
Why?
|
| Leukemia | 1 | 1988 | 54 | 0.070 |
Why?
|
| Oncogenes | 3 | 1995 | 44 | 0.070 |
Why?
|
| Restriction Mapping | 3 | 1994 | 42 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2013 | 259 | 0.070 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2003 | 57 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 458 | 0.070 |
Why?
|
| Japan | 1 | 2008 | 348 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 282 | 0.070 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2007 | 6 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 206 | 0.070 |
Why?
|
| Lymphocytes | 2 | 2013 | 124 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2019 | 69 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 575 | 0.070 |
Why?
|
| Karnofsky Performance Status | 1 | 2007 | 4 | 0.060 |
Why?
|
| Cytokines | 3 | 2017 | 678 | 0.060 |
Why?
|
| Recombination, Genetic | 1 | 2007 | 95 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 77 | 0.060 |
Why?
|
| Colon | 1 | 2007 | 120 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 134 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 2676 | 0.060 |
Why?
|
| Logistic Models | 1 | 2009 | 1009 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 27 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 3 | 1994 | 257 | 0.060 |
Why?
|
| Alleles | 1 | 2006 | 352 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 77 | 0.060 |
Why?
|
| Herpesviridae Infections | 1 | 2005 | 17 | 0.060 |
Why?
|
| Survival Rate | 2 | 2021 | 355 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 20 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2005 | 41 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2013 | 587 | 0.060 |
Why?
|
| Gene Rearrangement | 4 | 1992 | 17 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2018 | 1604 | 0.060 |
Why?
|
| Immunophenotyping | 3 | 1994 | 57 | 0.060 |
Why?
|
| Immunocompetence | 1 | 2004 | 10 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2005 | 91 | 0.050 |
Why?
|
| Polyneuropathies | 1 | 2004 | 9 | 0.050 |
Why?
|
| Etoposide | 3 | 2014 | 21 | 0.050 |
Why?
|
| Herpesvirus 8, Human | 1 | 2004 | 25 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2005 | 102 | 0.050 |
Why?
|
| Computer Systems | 1 | 2004 | 19 | 0.050 |
Why?
|
| Risk | 1 | 2004 | 287 | 0.050 |
Why?
|
| Apolipoproteins E | 1 | 2004 | 138 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 153 | 0.050 |
Why?
|
| Skin | 1 | 2005 | 187 | 0.050 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2003 | 3 | 0.050 |
Why?
|
| Genes, T-Cell Receptor delta | 1 | 2003 | 5 | 0.050 |
Why?
|
| Body Weight | 1 | 2005 | 429 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 1995 | 21 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2005 | 195 | 0.050 |
Why?
|
| Blood Cells | 1 | 2002 | 8 | 0.050 |
Why?
|
| Prevalence | 4 | 2011 | 1612 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2002 | 31 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2003 | 67 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2003 | 968 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2002 | 81 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 79 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2003 | 161 | 0.050 |
Why?
|
| Pregnancy | 2 | 2011 | 1772 | 0.050 |
Why?
|
| Neutrophils | 1 | 2023 | 145 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2007 | 392 | 0.050 |
Why?
|
| Remission Induction | 2 | 2014 | 19 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 16 | 0.050 |
Why?
|
| United States | 3 | 2020 | 5205 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 863 | 0.050 |
Why?
|
| Cell Line | 3 | 2009 | 1410 | 0.050 |
Why?
|
| Histones | 1 | 2023 | 197 | 0.050 |
Why?
|
| Disease Progression | 2 | 2019 | 667 | 0.050 |
Why?
|
| HIV Protease Inhibitors | 1 | 2001 | 24 | 0.040 |
Why?
|
| Blood | 1 | 2001 | 37 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2015 | 411 | 0.040 |
Why?
|
| Anthracyclines | 1 | 2021 | 8 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1994 | 139 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 245 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 526 | 0.040 |
Why?
|
| Health Status Disparities | 2 | 2019 | 719 | 0.040 |
Why?
|
| Education, Continuing | 1 | 2020 | 18 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 113 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2009 | 518 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| Capacity Building | 1 | 2020 | 99 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2009 | 2157 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 611 | 0.040 |
Why?
|
| Neopterin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2018 | 8 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 2853 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2019 | 171 | 0.040 |
Why?
|
| Cytarabine | 2 | 2014 | 10 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1124 | 0.030 |
Why?
|
| Oligonucleotide Probes | 2 | 1995 | 21 | 0.030 |
Why?
|
| Research Personnel | 1 | 2019 | 206 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 2019 | 193 | 0.030 |
Why?
|
| Introns | 2 | 2001 | 79 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 1995 | 6 | 0.030 |
Why?
|
| Genes, tat | 1 | 1995 | 8 | 0.030 |
Why?
|
| Age Distribution | 2 | 2007 | 249 | 0.030 |
Why?
|
| Typhlitis | 1 | 2014 | 1 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 35 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 53 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fes | 1 | 1994 | 3 | 0.030 |
Why?
|
| Receptors, CCR5 | 1 | 2014 | 64 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2015 | 138 | 0.030 |
Why?
|
| AIDS-Related Complex | 1 | 1994 | 2 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 116 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 70 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2013 | 64 | 0.030 |
Why?
|
| Focus Groups | 1 | 2015 | 423 | 0.030 |
Why?
|
| Half-Life | 1 | 2013 | 63 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 64 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 159 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 1990 | 63 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 704 | 0.020 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2012 | 4 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2012 | 9 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 490 | 0.020 |
Why?
|
| DNA Viruses | 1 | 2012 | 14 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 301 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 209 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 58 | 0.020 |
Why?
|
| Ghana | 1 | 1991 | 36 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 32 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2011 | 33 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1991 | 199 | 0.020 |
Why?
|
| Pharmacology | 1 | 2010 | 6 | 0.020 |
Why?
|
| Allergy and Immunology | 1 | 2010 | 14 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2010 | 27 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1990 | 49 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2008 | 279 | 0.020 |
Why?
|
| Complement Activation | 1 | 2009 | 14 | 0.020 |
Why?
|
| Neurosciences | 1 | 2010 | 34 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 74 | 0.020 |
Why?
|
| Biology | 1 | 1989 | 20 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 704 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 2 | 0.020 |
Why?
|
| Carboplatin | 1 | 2009 | 20 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2013 | 1413 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2009 | 80 | 0.020 |
Why?
|
| Mentors | 1 | 2010 | 145 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 94 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2009 | 109 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 94 | 0.020 |
Why?
|
| Internet | 1 | 2010 | 236 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 209 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 989 | 0.020 |
Why?
|
| Pyridines | 1 | 2009 | 139 | 0.020 |
Why?
|
| Neurons | 1 | 2015 | 1263 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 102 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2007 | 18 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2009 | 190 | 0.020 |
Why?
|
| Morbidity | 1 | 2007 | 97 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 306 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2006 | 18 | 0.020 |
Why?
|
| Phenotype | 2 | 2004 | 780 | 0.020 |
Why?
|
| Memory | 1 | 2007 | 174 | 0.010 |
Why?
|
| Interleukin-6 | 2 | 1995 | 165 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2001 | 20 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 737 | 0.010 |
Why?
|
| RNA | 2 | 1995 | 266 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2001 | 42 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 272 | 0.010 |
Why?
|
| Genes, Viral | 2 | 1991 | 61 | 0.010 |
Why?
|
| Virus Replication | 1 | 2002 | 318 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 6644 | 0.010 |
Why?
|
| Depression | 1 | 2004 | 863 | 0.010 |
Why?
|
| Life Tables | 1 | 1995 | 6 | 0.010 |
Why?
|
| Leucovorin | 1 | 1995 | 5 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1995 | 12 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1995 | 24 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1995 | 22 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 14 | 0.010 |
Why?
|
| Clone Cells | 1 | 1995 | 50 | 0.010 |
Why?
|
| Bleomycin | 1 | 1995 | 20 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1995 | 25 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 45 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1995 | 27 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1995 | 114 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1995 | 55 | 0.010 |
Why?
|
| Intestines | 1 | 1995 | 71 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1995 | 51 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 173 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1995 | 87 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1995 | 368 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1995 | 518 | 0.010 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1992 | 4 | 0.010 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1992 | 35 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1992 | 74 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1992 | 91 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 16992 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1990 | 41 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1990 | 127 | 0.000 |
Why?
|
| Cell Division | 1 | 1990 | 311 | 0.000 |
Why?
|
| Lung | 1 | 1992 | 492 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1991 | 430 | 0.000 |
Why?
|
| Time Factors | 1 | 1990 | 1857 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1991 | 495 | 0.000 |
Why?
|